Unveiling the Potential of the Ta:RNA™ Platform
We believe that our Ta:RNA™ platform can transform outcomes for a wide range of cancer patients.
Our Ta:RNA™ development programme is initially focused on three key receptor targets with our TAR001, TAR002 and TAR003 molecules.